Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04907279
Other study ID # 031-203-00468
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2021
Est. completion date June 2023

Study information

Verified date April 2022
Source Otsuka Canada Pharmaceutical Inc.
Contact Francois Therrien, Pharm.D.
Phone 15143323065
Email francois.therrien@otsuka-ca.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its clinical use in the proposed patient population, including time to discharge, efficacy, safety, tolerability, and patients' satisfaction.


Description:

This is a non-interventional, Canadian, prospective multi-site study in schizophrenia, schizoaffective disorder and BP1 among in-patients treated with AOM at the discretion of the treating physician and followed for the duration of their hospital stay. With the objective of characterizing the real-life, in-patient clinical uses of AOM, this study will not impose any treatments outside of what is recommended by the attending physician. As such, only patients admitted into hospital and prescribed AOM as a part of their physician's treatment recommendation will be included in this study. Study assessments and administration of questionnaires will be limited to baseline measurements occurring within the first 72 hours of AOM administration and at the end of study participation. All patients will be treated with AOM at the dose that is as per the treating physician's judgment. The decision to treat the patient with AOM must be reached independently and in advance of recruitment in the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: 1. The patient is between the age of majority (18 or 19 depending on the province) and 64 years of age inclusively; 2. The patient is currently hospitalized for the treatment of schizophrenia, schizoaffective disorder or BP1; 3. The patient is diagnosed with schizophrenia, schizoaffective disorder, or BP1 as defined by DSM-5 criteria; 4. The treating physician reached the decision to treat the patient with AOM prior to and independently of soliciting the patient to participate in the study; 5. The patient initiated treatment with AOM prior to enrolment and in accordance with routine clinical practice, including the assessment of potential risks associated with the medication (e.g. suicidality); 6. The patient or legal guardian (if applicable and when allowable by law) signed an informed consent indicating the understanding of the study and allowing the use of their anonymous data for the purposes of the study; and 7. The patient and caregiver(s) (if applicable) is/are fluent in English or French, in order to be able to complete the patient-administered questionnaires. Exclusion Criteria: 1. As per clinical judgement of the treating physician, the patient is diagnosed with treatment-resistant schizophrenia; 2. The patient does not comprehend or refuses to sign the informed consent; 3. The patient is unlikely to comply with study procedures according to the clinical judgment of the investigator; 4. The patient has any contraindications to the use of AOM as specified in the Canadian Product Monograph; 5. The patient is a member of the study personnel or of their immediate families or is a subordinate (or immediate family member of a subordinate) to any of the study personnel; 6. The patient has previously been enrolled in this study.

Study Design


Intervention

Drug:
Aripiprazole Once-Monthly (AOM)
Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.

Locations

Country Name City State
Canada Ottawa Hospital, Civic Campus Ottawa Ontario

Sponsors (2)

Lead Sponsor Collaborator
Otsuka Canada Pharmaceutical Inc. Lundbeck Canada Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average dose of Aripiprazole Once Monthly (AOM) The average total dose of AOM administered (number of mg and frequency of administration) during the hospitalization period will be evaluated Through study completion, an average of 3 weeks
Secondary Duration of hospital stay Number of days between initiation of AOM and termination of hospital stay Through study completion, an average of 3 weeks
Secondary Clinical Global Impression-Improvement (CGI-I) score Mean change in clinical symptom severity from baseline Through study completion, an average of 3 weeks
Secondary Global Impression-Severity of Illness (CGI-S) score Mean global severity of clinical symptoms Through study completion, an average of 3 weeks
Secondary Personal and Social Performance (PSP) score Mean psycho-social functioning score Through study completion, an average of 3 weeks
Secondary Medication Satisfaction Questionnaire (MSQ) score Mean score/level of satisfaction with current treatment administered Through study completion, an average of 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A